A Pilot Phase IIa Randomised, Double-Blind, Placebo-Controlled, Crossover Study to Examine the Safety, Tolerability and Pharmacodynamic Effects on Blood Pressure of Repeat Oral Doses of SLx-2101 5, 10 or 20 mg Once Daily for up to 14 Days in Patients With Hypertension.
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2011
At a glance
- Drugs KD 027 (Primary)
- Indications Hypertension
- Focus Therapeutic Use
- 17 Dec 2008 Official Title amended as reported by ClinicalTrials.gov.
- 17 Dec 2008 Primary outcome amended as reported by ClinicalTrials.gov.
- 17 Dec 2008 Actual end date (Dec 2007) added as reported by ClinicalTrials.gov.